OR WAIT null SECS
July 31, 2024
Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.
July 30, 2024
Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.
The agreement focuses on augmenting the patient support experience, including from an adherence perspective.
July 29, 2024
The partnership—which features a $150 million investment—is also centered around vaccine development in the respiratory and immunology space.
A cohort study investigates whether or not the prevalence of these types of illnesses can vary among individuals who are COVID-positive versus negative.
July 26, 2024
The pre-approval pertains to a solid oral dose product that the CDMO will manufacture for a global pharmaceutical company.
Making connections between different datasets is essential to developing impactful medicines and driving more personalized patient care.
July 25, 2024
The acquisition provides Ardian with greater insight into the life science industry.
The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.
July 24, 2024
A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.